JP2023522693A - Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置 - Google Patents

Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置 Download PDF

Info

Publication number
JP2023522693A
JP2023522693A JP2022563376A JP2022563376A JP2023522693A JP 2023522693 A JP2023522693 A JP 2023522693A JP 2022563376 A JP2022563376 A JP 2022563376A JP 2022563376 A JP2022563376 A JP 2022563376A JP 2023522693 A JP2023522693 A JP 2023522693A
Authority
JP
Japan
Prior art keywords
carbonyl
amino
pyrimidin
pyrazolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522693A5 (OSRAM
Inventor
クレア・ラングリッシュ
ドルカ・トーマス
ステファニ・ウォルフ
Original Assignee
プリンシピア バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリンシピア バイオファーマ インコーポレイテッド filed Critical プリンシピア バイオファーマ インコーポレイテッド
Publication of JP2023522693A publication Critical patent/JP2023522693A/ja
Publication of JP2023522693A5 publication Critical patent/JP2023522693A5/ja
Priority to JP2025187946A priority Critical patent/JP2026027386A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022563376A 2020-04-22 2021-04-21 Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置 Pending JP2023522693A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025187946A JP2026027386A (ja) 2020-04-22 2025-11-07 Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013784P 2020-04-22 2020-04-22
US63/013,784 2020-04-22
PCT/US2021/028381 WO2021216696A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025187946A Division JP2026027386A (ja) 2020-04-22 2025-11-07 Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置

Publications (2)

Publication Number Publication Date
JP2023522693A true JP2023522693A (ja) 2023-05-31
JP2023522693A5 JP2023522693A5 (OSRAM) 2024-05-01

Family

ID=75919390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563376A Pending JP2023522693A (ja) 2020-04-22 2021-04-21 Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置
JP2025187946A Pending JP2026027386A (ja) 2020-04-22 2025-11-07 Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025187946A Pending JP2026027386A (ja) 2020-04-22 2025-11-07 Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置

Country Status (12)

Country Link
US (1) US20230158031A1 (OSRAM)
EP (1) EP4138836A1 (OSRAM)
JP (2) JP2023522693A (OSRAM)
KR (1) KR20230015346A (OSRAM)
CN (1) CN115443136A (OSRAM)
AU (1) AU2021261327A1 (OSRAM)
BR (1) BR112022020974A2 (OSRAM)
CA (1) CA3175788A1 (OSRAM)
IL (1) IL297316A (OSRAM)
MX (1) MX2022013164A (OSRAM)
TW (1) TW202206076A (OSRAM)
WO (1) WO2021216696A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517838A (ja) * 2011-05-17 2014-07-24 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
JP2015527401A (ja) * 2012-09-10 2015-09-17 プリンシピア バイオファーマ インコーポレイテッド キナーゼ阻害剤としてのピラゾロピリミジン化合物
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EA027561B1 (ru) * 2011-11-03 2017-08-31 Ф.Хоффманн-Ля Рош Аг Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
EP3082809B1 (en) * 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2021211782A1 (en) * 2020-04-15 2021-10-21 Telios Pharma, Inc. Methods of treating acute lung injury and acute respiratory distress syndrome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517838A (ja) * 2011-05-17 2014-07-24 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
JP2015527401A (ja) * 2012-09-10 2015-09-17 プリンシピア バイオファーマ インコーポレイテッド キナーゼ阻害剤としてのピラゾロピリミジン化合物
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM J RESPIR CRIT CARE MED, vol. 199, JPN6025022950, 2019, pages 1695, ISSN: 0005743254 *
CELL BIOCHEM BIOPHYS, vol. 70, JPN6025022949, 2014, pages 1265 - 1275, ISSN: 0005743255 *

Also Published As

Publication number Publication date
IL297316A (en) 2022-12-01
BR112022020974A2 (pt) 2022-12-06
WO2021216696A1 (en) 2021-10-28
MX2022013164A (es) 2022-11-30
CN115443136A (zh) 2022-12-06
JP2026027386A (ja) 2026-02-18
TW202206076A (zh) 2022-02-16
EP4138836A1 (en) 2023-03-01
KR20230015346A (ko) 2023-01-31
CA3175788A1 (en) 2021-10-28
US20230158031A1 (en) 2023-05-25
AU2021261327A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
TW202142230A (zh) 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法
D’Cruz et al. Novel Bruton’s tyrosine kinase inhibitors currently in development
CN117205312A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
EP3303399A1 (en) Methods of treating cancer using anti-ox40 antibodies
AU2020257041C1 (en) Crystalline forms of C21H22CI2N4O2
AU2020280272B2 (en) Methods of treating Chronic Spontaneous Urticaria using a Bruton's tyrosine kinase inhibitor
Esnault et al. IL‐3 up‐regulates and activates human eosinophil CD 32 and αMβ2 integrin causing degranulation
JP2026027386A (ja) Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置
AU2019247498A1 (en) AXL kinase inhibitors and use of the same
KR20260051402A (ko) Ras 단백질 관련 질환 또는 장애의 치료에서의 사용을 위한 rmc-6291
JP2025134877A (ja) ＢＴＫ阻害剤２－［（３Ｒ）－３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを使用する、膜性腎症、ＩＧＧ４関連疾患、及び抗リン脂質症候群の処置
Zhao et al. A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or-dependent chronic GVHD
Kamenova et al. Recent advances in the treatment of systemic sclerosis associated interstitial lung disease
JP2019172708A (ja) 二重ｐｉ３ｋデルタ‐ガンマキナーゼ阻害剤及びコルチコステロイドを含む治療方法及び組成物
CA3236111A1 (en) Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide
CN120285174A (zh) 抗vegf抗体与parp抑制剂联合用于治疗肿瘤
CN115175682A (zh) 使用布鲁顿氏酪氨酸激酶的抑制剂治疗原发进展型多发性硬化症的方法
WO2023250367A1 (en) Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide
US20260078198A1 (en) Methods for treating cancer using subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin
US20260109777A1 (en) Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide
US20230190932A1 (en) Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide
Gregory et al. Upadacitinib for the Treatment of Pyoderma Gangrenosum: a Literature Review
TW202348626A (zh) 用莫蘇妥珠單抗及來那度胺治療復發性／難治性濾泡性淋巴瘤之方法
Millet et al. BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations
JP2025527297A (ja) Ｊａｋ阻害剤を使用した蕁麻疹の処置

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202